Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

OXBDF RSS Feed
Add OXBDF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/20/2020 2:08:22 PM - Followers: 7 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
 
Trades In UK as (OXB.L)
  
  
Company website

UK company traded on grey's in US

 

 
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

 
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
 
Management
 
Partnerships 
 
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
 
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
 
 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
 
 
 
 
 
OXBDF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#797   Oxford coronavirus vaccine induces strong immune response georgejjl 07/20/20 02:08:22 PM
#796   Safety and Immunogenicity of Novel 5T4 Viral Vectored georgejjl 07/09/20 05:54:57 PM
#795   Oxford Biomedica snags manufacturing equipment to ramp up georgejjl 06/26/20 09:43:19 PM
#794   AstraZeneca agrees to make COVID-19 vaccine for Europe georgejjl 06/13/20 01:03:59 PM
#793   AstraZeneca Approaches Gilead About Potential Merger georgejjl 06/07/20 01:37:54 PM
#792   AstraZeneca is aiming to produce 2 billion doses georgejjl 06/04/20 04:17:46 PM
#791   AstraZeneca locks up COVID-19 vaccine supply with Oxford georgejjl 05/28/20 07:27:11 PM
#790   Oxford Biomedica Signs Clinical & Commercial Supply Agreement georgejjl 05/28/20 09:03:10 AM
#789   The Oxford COVID-19 vaccine is 'progressing very well,' georgejjl 05/22/20 07:34:28 PM
#788   U.S. to invest $1.2 billion to secure potential georgejjl 05/21/20 05:13:10 PM
#787   U.S. to invest $1.2 billion to secure potential georgejjl 05/21/20 05:12:34 PM
#786   AstraZeneca Aims for 30 Million U.K. Vaccine Doses georgejjl 05/17/20 10:06:12 PM
#785   HTTps://www.youtube.com/watch?v=-sGNsKpmB-c marcusl2 05/17/20 08:26:14 AM
#784   Nine Ten Capital Management LLC Buys , Oxford marcusl2 05/17/20 08:24:14 AM
#783   Monkey trial of Oxford vaccine shows encouraging results georgejjl 05/15/20 11:37:11 PM
#782   In April the Group has joined a Consortium georgejjl 05/15/20 09:13:02 PM
#781   Oxford Biomedica bags MHRA nod for two manufacturing suites georgejjl 05/13/20 08:30:45 PM
#780   John Dawson, Chief Executive Officer of Oxford Biomedica, said: marcusl2 05/13/20 04:06:05 AM
#779   Emily Whitehead past, present and FUTURE georgejjl 05/09/20 12:13:14 PM
#778  Restored Oxford scientist says its vaccine is making headway, georgejjl 05/03/20 05:32:23 PM
#777  Restored Bill Gates says the world would need as georgejjl 05/03/20 09:13:02 AM
#776   Coronavirus vaccine update: How far along is the georgejjl 05/02/20 07:50:10 AM
#775   Bill Gates says the world will need 7 georgejjl 04/30/20 07:39:58 PM
#774   The Jenner Institute at Oxford University made the georgejjl 04/30/20 07:16:41 PM
#773   AstraZeneca enters deal to manufacture University of Oxford's georgejjl 04/30/20 06:11:42 PM
#772   In Race for a Coronavirus Vaccine, an Oxford georgejjl 04/28/20 07:48:13 PM
#771   Good News on Oxford Vaccine Is Bright Spot georgejjl 04/28/20 07:42:30 PM
#770   6 monkeys given an experimental coronavirus vaccine from georgejjl 04/28/20 01:27:18 PM
#769   University of Oxford coronavirus vaccine trial aims to georgejjl 04/17/20 04:30:05 PM
#768   The COVID 19 trial with ChAdOx1 nCov-19 georgejjl 04/08/20 10:29:43 PM
#767   https://www.edisongroup.com/wp-content/uploads/2020/04/Oxford-BioMedica-Juno-dea marcusl2 04/08/20 04:32:53 PM
#766   Oxford Biomedica joins Consortium to rapidly develop a georgejjl 04/08/20 06:54:06 AM
#765   AXO-Lenti-PD http://investors.axovant.com/static-files/986b7b10-3d28-4afc-947 georgejjl 03/30/20 08:38:32 PM
#764   AXO-Lenti-PD delivers a 22-point (44%) improvement from baseline marcusl2 02/23/20 04:29:46 AM
#763   British scientists accidentally discover immune cell that 'may georgejjl 01/23/20 07:55:02 AM
#762   Harnessing the immune system to fight cancer could georgejjl 01/22/20 08:28:16 PM
#761   Immune discovery 'may treat all cancer' georgejjl 01/20/20 11:24:48 PM
#760   Gene Therapy for Parkinson's Disease: Preclinical Evaluation of georgejjl 01/05/20 01:46:39 PM
#759   https://www.evaluate.com/vantage/articles/analysis/plenty-choice-remains-buyers- marcusl2 12/21/19 09:45:43 AM
#758   Oxford Biomedica PLC marcusl2 12/19/19 08:59:31 AM
#757   AXO-Lenti-PD http://investors.axovant.com/static-files/b6b0cded-8d58-46d4-99a georgejjl 12/03/19 09:54:40 PM
#756   Novartis's $90 million Swiss factory to help solve georgejjl 11/29/19 06:19:25 PM
#755   Novartis, Vertex outline big gene therapy plans — georgejjl 11/27/19 05:58:27 PM
#754   Novartis Q3 Results: marcusl2 10/22/19 10:11:01 AM
#753   Oxford Biomedica (OXB) - Burgeoning bioprocessing revenues marcusl2 09/05/19 10:37:54 AM
#752   Oxford Biomedica is about to clinch new marcusl2 09/05/19 04:16:36 AM
#751   Gene Therapy for Parkinson’s Disease: Preclinical Evaluation of georgejjl 08/31/19 04:17:07 PM
#750   Robert has a proven track record of helping marcusl2 06/25/19 07:38:39 AM
#749   In a cell and gene therapy sweet spot georgejjl 06/04/19 07:54:09 AM
#748   GREAT NEWS!!! georgejjl 05/28/19 08:01:32 PM
PostSubject